Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sandra Coppens is active.

Publication


Featured researches published by Sandra Coppens.


Journal of Virological Methods | 1998

Design and evaluation of an in-house HIV-1 (group M and O), SIVmnd and SIVcpz antigen capture assay.

Els Beirnaert; Betty Willems; M. Peeters; A Bouckaert; Leo Heyndrickx; Ping Zhong; Katleen Vereecken; Sandra Coppens; David Davis; Peter M. Ndumbe; Wouter Janssens; G. van der Groen

An enzyme-linked immuno-sorbent assay (ELISA) for the detection of human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIVcpz/SIVmnd) antigens was designed using immunoreagents from naturally infected individuals, and compared to the commercially available Vironostika HIV-1 Antigen Microelisa System (Organon Teknika). The in-house assay proved to be specific for HIV-1 isolates belonging to group M (A-H) and group O and for SIVcpz and SIVmnd isolates, but was less sensitive than the Vironostika HIV-1 Antigen Microelisa System, except for SIVmnd. For the strains belonging to HIV-2, SIVmac and SIVagm, the in-house assay could not detect antigen to an appreciable degree. This study shows that a considerably less expensive but sufficiently accurate HIV-1 antigen capture assay can be developed to monitor HIV-1 (group M and O), SIVcpv and SIVmnd antigen in the supernatants of virus cultures.


AIDS | 2002

Predominance of infection with HIV-1 circulating recombinant form CRF02_AG in major Cameroonian cities and towns.

Phillipe N. Nyambi; Leo Heyndrickx; Katleen Vereecken; Sherri Burda; Kathleen De Houwer; Sandra Coppens; Mateusz M. Urbanski; Constance Williams; Peter M. Ndumbe; Wouter Janssens

Our observations add to previous results on molecular epidemiology in different provinces in Cameroon demonstrating a high prevalence of CRF02_AG and subtype A accounting for 90% of circulating HIV-1 strains. The country-wide high prevalence of HIV-1 CRF02_AG in Cameroon compared with the relatively low prevalence of CRF02_AG in the Democratic Republic of Congo suggest an early founder effect of this AG recombinant in West Central Africa initiating major CRF02 epidemics. (excerpt)


AIDS | 1999

Interpatient genetic variability of HIV-1 group O.

Wouter Janssens; Leo Heyndrickx; Gert Van Der Auwera; John N. Nkengasong; Els Beirnaert; Katleen Vereecken; Sandra Coppens; Betty Willems; Katrien Fransen; Martine Peeters; Peter M. Ndumbe; Eric Delaporte; Guido van der Groen

OBJECTIVE To analyse the genetic and phylogenetic characteristics of HIV-1 group O viruses. MATERIALS AND METHODS The env gene, encoding the gp160 glycoprotein, and a partial p24-encoding gag gene fragment of a Cameroonian (CA9) and a Gabonese (VI686) HIV-1 group O virus, isolated from cultured peripheral blood mononuclear cells of symptomatic patients, were sequenced, aligned with other representatives of group O for which the same region has been documented, and genetically and phylogenetically analysed. RESULTS Phylogenetic analysis of the env gene (gp160) revealed that CA9, VI686, ANT70, and four Ha strains formed a separate cluster, which was supported by 100% of all bootstrap trees. In addition, these seven isolates were part of the same clade in the p24 phylogeny. VAU and MVP5180 may represent two other subtypes. CONCLUSION We have characterized two group O viruses, originating from Cameroon and Gabon, which show a close evolutionary relationship to ANT70 and four Ha strains based on the entire env gene, suggestive of a first group O subgroup, tentatively named the HIV-1 group O env ANT70 clade or subtype.


PLOS ONE | 2012

Immune and Viral Correlates of "Secondary Viral Control" after Treatment Interruption in Chronically HIV-1 Infected Patients

Ellen Van Gulck; Lotte L. Bracke; Leo Heyndrickx; Sandra Coppens; Derek Atkinson; Céline Merlin; Alexander O. Pasternak; Eric Florence; Guido Vanham

Upon interruption of antiretroviral therapy, HIV-infected patients usually show viral load rebound to pre-treatment levels. Four patients, hereafter referred to as secondary controllers (SC), were identified who initiated therapy during chronic infection and, after stopping treatment, could control virus replication at undetectable levels for more than six months. In the present study we set out to unravel possible viral and immune parameters or mechanisms of this phenomenon by comparing secondary controllers with elite controllers and non-controllers, including patients under HAART. As candidate correlates of protection, virus growth kinetics, levels of intracellular viral markers, several aspects of HIV-specific CD4+ and CD8+ T cell function and HIV neutralizing antibodies were investigated. As expected all intracellular viral markers were lower in aviremic as compared to viremic subjects, but in addition both elite and secondary controllers had lower levels of viral unspliced RNA in PBMC as compared to patients on HAART. Ex vivo cultivation of the virus from CD4+ T cells of SC consistently failed in one patient and showed delayed kinetics in the three others. Formal in vitro replication studies of these three viruses showed low to absent growth in two cases and a virus with normal fitness in the third case. T cell responses toward HIV peptides, evaluated in IFN-γ ELISPOT, revealed no significant differences in breadth, magnitude or avidity between SC and all other patient groups. Neither was there a difference in polyfunctionality of CD4+ or CD8+ T cells, as evaluated with intracellular cytokine staining. However, secondary and elite controllers showed higher proliferative responses to Gag and Pol peptides. SC also showed the highest level of autologous neutralizing antibodies. These data suggest that higher T cell proliferative responses and lower replication kinetics might be instrumental in secondary viral control in the absence of treatment.


AIDS Research and Human Retroviruses | 2000

Study of HIV Type 1 gag/env Variability in The Gambia, Using a Multiplex DNA Polymerase Chain Reaction

Fatim Cham; Leo Heyndrickx; Wouter Janssens; Gert Van Der Auwera; Katleen Vereecken; Kathleen De Houwer; Sandra Coppens; Hilton Whittle; Guido van der Groen

A multiplex DNA PCR assay was developed for the simultaneous first-round amplification of HIV-1 gag and env fragments for the heteroduplex mobility assay (HMA). This assay was compared with the conventional amplification assay, using DNA extracted from PBMC samples from 30 HIV-1-seropositive individuals from The Gambia, who were enrolled between 1992 and 1997. From 27 of 30 (90%) samples both gag and env HMA fragments were amplified simultaneously. In one sample only the gag HMA fragment could be amplified by multiplex DNA PCR, and in two samples amplification was negative for both gag and env HMA in multiplex as well as the mono-DNA PCR. Of the 28 Gambian isolates subtyped by gag/env HMA or by sequencing and phylogenetic analysis, the majority (19 of 28; 68%) were intersubtype recombinant. Fifteen of 28 (53%) samples were circulating recombinant form (CRF) CRF02.AG variants. Two isolates clustering with the previously documented Gambian isolate GM4 (previously described as an env GC recombinant) are classified as gag A/env J recombinants.


Journal of Virological Methods | 2008

Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays

Leo Heyndrickx; Tine Vermoesen; Katleen Vereecken; Julia Kurth; Sandra Coppens; Laetitia Aerts; Asa Ohagen; Yven Van Herrewege; Paul J. Lewi; Guido Vanham

HIV-1 Env pseudotyped viruses (PV) are an attractive tool for studying the antiviral activities of compounds interfering with virus entry into a target cell. To investigate whether results obtained in PV assays are relevant biologically, the antiviral activity of 6 reference compounds was compared on 5 virus isolates of different clades using three assays: (1) replicating virus in peripheral blood mononuclear cells (PBMCs), (2) PV in CD4 and CCR5- or CXCR4 co-receptor expressing Ghost cells, and (3) PV in PBMCs. A significant linear relationship was found between both single-cycle PV assays (P<0.0001, R2=0.75). Moreover, both assays showed enhanced sensitivity to the antiretrovirals tested (P=0.013 and 0.015, respectively) as compared to the PBMC assay with replication-competent virus. Most importantly, results from the latter assay could be predicted significantly from both PV assays, in which either Ghost target cells (P<0.0001, R2=0.61) or PBMCs (P<0.0001, R2=0.55) were used. The usefulness of the PV assay was demonstrated further by investigating the impact of the HIV-1 Env subtype on the antiviral activity of five new compounds derived from the entry inhibitor BMS806.


Journal of Virological Methods | 2010

Unravelling the antigenic landscape of the HIV-1 subtype A envelope of an individual with broad cross-neutralizing antibodies using phage display peptide libraries

Tessa Dieltjens; Betty Willems; Sandra Coppens; Lies Van Nieuwenhove; Michael Humbert; Ursula Dietrich; Leo Heyndrickx; Guido Vanham; Wouter Janssens

Broad cross-neutralizing antibodies from persons infected with HIV-1 target a variety of epitopes. Identification of these HIV-1 epitopes may result in an optimal panel of antigenic peptides to be included in a prophylactic vaccine. Phage display peptide libraries were used to unravel the antigenic landscape of an individual (ITM1) infected with HIV-1 subtype A with broad cross-neutralizing antibodies. A stringent selection strategy resulted in the identification of 60 unique HIV-1 peptide phage, which were subjected to sequence analysis and mapped onto the ITM1 envelope sequences. Four groups of peptide phages were found: the first group (n=11) were similar with the tip of the V3 loop (KxxHxGPxxxF); the second group (n=11) represented the gp41 principal immunodominant domain (CxGxLxCTxNxP); the third group (n=16) could be localized in the V2 loop (KxxxHxxxY); and the fourth group (n=22) mimicked a conformational epitope (Hxx(S)/(T)NxK). All but the V2-binding antibodies were conserved over the 11 years of follow-up. A neutralization inhibition assay revealed the contribution of the V3 antibodies to the neutralizing capacity of the ITM1 plasma. Overall, the ITM1 immunogenic landscape was mapped and a part of the origin of this broad cross-neutralizing activity was demonstrated.


AIDS Research and Human Retroviruses | 2000

Development of a One-Tube Multiplex Reverse Transcriptase-Polymerase Chain Reaction Assay for the Simultaneous Amplification of HIV Type 1 Group M gag and env Heteroduplex Mobility Assay Fragments

Fatim Cham; L. E. O. Heyndrickx; Wouter Janssens; Katleen Vereecken; Kathleen De Houwer; Sandra Coppens; Gert Van Der Auwera; Hilton Whittle; Guido van der Groen

The emergence of intersubtype recombinant HIV-1 isolates has made it imperative to analyze different regions of HIV-1 genomes. For this purpose a one-tube multiplex RT-PCR, coamplifying first-round amplicons that allow amplification of gag and env heteroduplex mobility assay (HMA) fragments from different HIV-1 group M isolates, was developed, starting with plasma samples. The multiplex RT-PCR assay is sensitive: 115 of 136 (84.5%) samples were positive for both gag and env, positive amplification of the gag fragment was observed in 130 of 136 (95.6%) samples, while for the env fragment 119 of 136 (87.5%) tested positive. The multiplex RT-PCR in combination with gag and env HMA makes large-scale HIV-1 subtyping fast, simple, and more economical.


PLOS ONE | 2012

Molecular Epidemiology of HIV-1 Transmission in a Cohort of HIV-1 Concordant Heterosexual Couples from Dakar, Senegal

Wim Jennes; Jordan K. Kyongo; Evelyn Vanhommerig; Makhtar Camara; Sandra Coppens; M. Seydi; Souleymane Mboup; Leo Heyndrickx; Luc Kestens

Background A large number of HIV-1 infections in Africa occur in married couples. The predominant direction of intracouple transmission and the principal external origins of infection remain important issues of debate. Methods We investigated HIV-1 transmission in 46 HIV-1 concordant positive couples from Dakar, Senegal. Intracouple transmission was confirmed by maximum-likelihood phylogenetic analysis and pairwise distance comparisons of HIV-1 env gp41 sequences from both partners. Standardized interview data were used to deduce the direction as well as the external sources of the intracouple transmissions. Results Conservative molecular analyses showed linked viruses in 34 (74%) couples, unlinked viruses in 6 (13%) couples, and indeterminate results for 6 (13%) couples. The interview data corresponded completely with the molecular analyses: all linked couples reported internal transmission and all unlinked couples reported external sources of infection. The majority of linked couples (93%) reported the husband as internal source of infection. These husbands most frequently (82%) reported an occasional sexual relationship as external source of infection. Pairwise comparisons of the CD4 count, antiretroviral therapy status, and the proportion of gp41 ambiguous base pairs within transmission pairs correlated with the reported order of infection events. Conclusions In this suburban Senegalese population, a majority of HIV-1 concordant couples showed linked HIV-1 transmission with the husband as likely index partner. Our data emphasize the risk of married women for acquiring HIV-1 as a result of the occasional sexual relationships of their husbands.


AIDS Research and Human Retroviruses | 1999

Intrapatient Variability of HIV Type 1 Group O ANT70 during a 10-Year Follow-up

Wouter Janssens; John N. Nkengasong; Leo Heyndrickx; Gert Van Der Auwera; Katleen Vereecken; Sandra Coppens; Betty Willems; Els Beirnaert; Katrien Fransen; Martine Peeters; Guido van der Groen

HIV-1 ANT70 is the first HIV-1 group O virus isolate obtained from a 25-year-old Cameroonian woman, who seroconverted in March 1987. This individual has remained asymptomatic and clinically healthy (clinical stage WHO 1, CDC II) even though she did not receive any antiretroviral therapy for HIV-1 before 97 months post-seroconversion. CD4+ T cell counts declined steadily to 200/microl at 70 months postseroconversion. The HIV-1 ANT70 nucleotide and amino acid sequence diversity of the V3C3-encoding env fragment within this individual was followed over a 10-year period. RT-PCR, cloning, sequencing, and genetic analyses were performed on eight plasma follow-up samples. Extensive increasing intra- and intersample variation was observed. This is the first long-term (>10 years) follow-up of the genetic variability of an HIV-1 group O-infected individual. As the course of the disease in the HIV-1 ANT70-infected woman was similar in many aspects to that of group M-infected individuals, it remains to be elucidated whether the changes observed in the V3 loop are critical for disease progression.

Collaboration


Dive into the Sandra Coppens's collaboration.

Top Co-Authors

Avatar

Leo Heyndrickx

Institute of Tropical Medicine Antwerp

View shared research outputs
Top Co-Authors

Avatar

Katleen Vereecken

Institute of Tropical Medicine Antwerp

View shared research outputs
Top Co-Authors

Avatar

Wouter Janssens

Institute of Tropical Medicine Antwerp

View shared research outputs
Top Co-Authors

Avatar

Betty Willems

Institute of Tropical Medicine Antwerp

View shared research outputs
Top Co-Authors

Avatar

Guido van der Groen

Institute of Tropical Medicine Antwerp

View shared research outputs
Top Co-Authors

Avatar

Katrien Fransen

Institute of Tropical Medicine Antwerp

View shared research outputs
Top Co-Authors

Avatar

Guido Vanham

Free University of Brussels

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fatim Cham

Uniformed Services University of the Health Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge